⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4384590 | 0.62 | — | — | |
| Methoxymethane SCHEMBL28497280 | 0.45 | — | — | |
| Methoxymethane SCHEMBL28199675 | 0.41 | — | — | |
| Methoxymethane SCHEMBL28255990 | 0.41 | — | — | |
| SCHEMBL2374333 | 0.41 | — | — | |
| SCHEMBL192237 | 0.41 | — | — | |
| Methoxymethane SCHEMBL28287621 | 0.41 | — | — | |
| SCHEMBL4326490 | 0.38 | — | — | |
| SCHEMBL3149451 | 0.38 | — | — | |
| SCHEMBL8749546 | 0.38 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023152371-A1 | GUIDE OLIGONUCLEOTIDES FOR NUCLEIC ACID EDITING IN THE TREATMENT OF HYPERCHOLESTEROLEMIA | PROQR THERAPEUTICS II B.V. (NL) | 2023-08-17 | — | — | WO | claimed |
| US-20230039928-A1 | Antisense oligonucleotides for nucleotide deamination in the treatment of Stargardt disease | PROQR THERAPEUTICS II B.V. (NL) | 2023-02-09 | — | — | US | claimed |
| WO-2021130313-A1 | ANTISENSE OLIGONUCLEOTIDES FOR NUCLEOTIDE DEAMINATION IN THE TREATMENT OF STARGARDT DISEASE | PROQR THERAPEUTICS II B.V. (NL) | 2021-07-01 | — | — | WO | claimed |
| EP-4400169-A2 | RNA MODULATING OLIGONUCLEOTIDES WITH IMPROVED CHARACTERISTICS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | Vico Therapeutics B.V. (NL) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024127026-A1 | MEMBRANE FILTRATION-ASSISTED SOLUTION PHASE OLIGONUCLEOTIDE SYNTHESIS | Exactmer Limited (GB) | 2024-06-20 | — | — | WO | disclosed |
| EP-3604536-B1 | RNA MODULATING OLIGONUCLEOTIDES WITH IMPROVED CHARACTERISTICS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | VICO THERAPEUTICS B V (NL) | 2024-05-29 | — | — | EP | disclosed |
| CN-118103384-A | Solution phase polymer synthesis | 艾克特姆有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-4370677-A1 | OLIGONUCLEOTIDE FOR INHIBITING QUAKING ACTIVITY | Academisch Ziekenhuis Leiden h.o.d.n. LUMC (NL) | 2024-05-22 | — | — | EP | disclosed |
| US-20240141340-A1 | ANTISENSE OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF CORNEAL DYSTROPHIES | PROQR THERAPEUTICS II B.V. (NL) | 2024-05-02 | — | — | US | disclosed |
| WO-2024084048-A1 | HETERODUPLEX RNA EDITING OLIGONUCLEOTIDE COMPLEXES | PROQR THERAPEUTICS II B.V. (NL) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024074663-A1 | ULTRAFILTRATION METHODS | BioSpring Gesellschaft für Biotechnologie mbH (DE) | 2024-04-11 | — | — | WO | disclosed |
| EP-2751283-A1 | PROCESS FOR SEPARATION OF OLIGONUCLEOTIDE OF INTEREST FROM A MIXTURE | Glaxo Group Limited (GB) | 2014-07-09 | — | — | EP | disclosed |
| EP-2699269-A1 | NEW COMPOUNDS FOR TREATING, DELAYING AND/OR PREVENTING A HUMAN GENETIC DISORDER SUCH AS MYOTONIC DYSTROPHY TYPE 1 (DM1) | Prosensa Technologies B.V. (NL) | 2014-02-26 | — | — | EP | disclosed |
| US-20140045763-A1 | COMPOUNDS FOR TREATING, DELAYING AND/OR PREVENTING A HUMAN GENETIC DISORDER SUCH AS MYOTONIC DYSTROPHY TYPE I (DMI) | PROSENSA TECHNOLOGIES B.V. (CH) | 2014-02-13 | — | — | US | disclosed |
| WO-2014011053-A1 | OLIGONUCLEOTIDES FOR MAKING A CHANGE IN THE SEQUENCE OF A TARGET RNA MOLECULE PRESENT IN A LIVING CELL | PROQR THERAPEUTICS B.V. (NL) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014007620-A2 | OLIGONUCLEOTIDE FOR THE TREATMENT OF MUSCULAR DYSTROPHY PATIENTS | PROSENSA TECHNOLOGIES B.V. (NL) | 2014-01-09 | — | — | WO | disclosed |
| WO-2013162363-A1 | RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders | PROSENSA TECHNOLOGIES B.V. (NL) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013112053-A1 | RNA MODULATING OLIGONUCLEOTIDES WITH IMPROVED CHARACTERISTICS FOR THE TREATMENT OF DUCHENNE AND BECKER MUSCULAR DYSTROPHY | PROSENSA TECHNOLOGIES B.V. (NL) | 2013-08-01 | — | — | WO | disclosed |
| WO-2013030263-A1 | PROCESS FOR SEPARATION OF OLIGONUCLEOTIDE OF INTEREST FROM A MIXTURE | GLAXO GROUP LIMITED (GB) | 2013-03-07 | — | — | WO | disclosed |
| WO-2012144906-A1 | NEW COMPOUNDS FOR TREATING, DELAYING AND/OR PREVENTING A HUMAN GENETIC DISORDER SUCH AS MYOTONIC DYSTROPHY TYPE 1 (DM1) | PROSENSA TECHNOLOGIES B.V. (NL) | 2012-10-26 | — | — | WO | disclosed |